How is TAVR volume expansion across risk tiers sustaining structural heart implant market growth?
TAVR system utilisation has progressively expanded from high-surgical-risk patients in initial pivotal trials to intermediate and low-risk patients following landmark trial evidence, with contemporary valve designs demonstrating 5-year valve durability outcomes that have allayed concerns about structural valve deterioration in younger patients. The expansion to low-risk younger patients has added a significantly larger patient population to the addressable TAVR indication, with prevalence of moderate-to-severe aortic stenosis estimated at approximately 1.7 million patients in the United States alone, the majority of whom are now potentially eligible for TAVR rather than restricted to surgical aortic valve replacement by high surgical risk thresholds.

What is driving left atrial appendage closure device adoption in non-valvular atrial fibrillation?
Left atrial appendage closure devices such as the Watchman FLX (Boston Scientific) and Amulet (Abbott) eliminate the LAA as the source of approximately 90 percent of cardioembolic thrombus in non-valvular AF, providing stroke prevention equivalent to warfarin anticoagulation at 2-year follow-up in PROTECT AF and PREVAIL trials, without the ongoing bleeding risk of lifelong anticoagulation therapy. The addressable patient population for LAA closure includes AF patients with contraindications to oral anticoagulation from prior major bleeding events, patients at high fall risk, and patients with triple antithrombotic therapy requirements — a large and growing segment of the AF population sustaining LAA closure device procedure volume growth.

How are next-generation bioresorbable coronary scaffolds addressing the limitations of first-generation BRS devices?
First-generation bioresorbable scaffolds including the Absorb BVS were withdrawn from global markets following ABSORB III trial results demonstrating higher target lesion failure rates than conventional drug-eluting metallic stents at 3-year follow-up, attributed to insufficient radial strength, thick strut profile limiting deliverability, and sub-optimal implantation technique standardisation. Next-generation bioresorbable scaffold designs incorporating ultrathin struts (100-150 microns versus 150-200 for Absorb), improved polymer crystallisation for enhanced radial strength, and dedicated implantation technique protocols are in clinical trial evaluation with encouraging early results sustaining investment interest in the bioresorbable scaffold technology approach despite first-generation outcomes.

How does the implantable hemodynamic monitoring device segment sustain above-implant-market growth?
Implantable hemodynamic monitoring devices — including the CardioMEMS HF System (Abbott) that measures pulmonary artery pressure wirelessly from a permanently implanted PA sensor — enable remote haemodynamic-guided heart failure management by detecting haemodynamic deterioration days before clinical symptoms manifest, enabling preemptive diuretic adjustment that reduces heart failure hospitalisation rates in the CHAMPION trial evidence. The growing adoption of PA pressure-guided heart failure management at advanced heart failure programmes is sustaining implantable hemodynamic monitor implantation revenue above traditional cardiac device categories.

What advances in septal occluder device technology are expanding structural hole closure indications?
Patent foramen ovale closure devices for secondary stroke prevention in cryptogenic stroke patients below 60 years of age received strong randomised trial support from CLOSE, REDUCE, and DEFENSE-PFO trials demonstrating significant reduction in recurrent stroke risk versus antiplatelet therapy alone. ASD closure devices are growing from expanding percutaneous closure capability into larger defects previously managed surgically, with new self-expanding occluder designs accommodating defects up to 38 mm in diameter within catheter-based delivery. VSD closure devices are expanding into muscular VSD repair and post-myocardial infarction VSD closure as transcatheter approaches reduce the prohibitive surgical mortality of emergency VSD repair.

Which cardiac implant segments are growing fastest?
TAVR and transcatheter structural heart valve implants expanding across risk tiers, LAA closure device adoption in anticoagulation-ineligible AF patients, PA pressure-guided heart failure management hemodynamic monitor implantation, and PFO closure for secondary stroke prevention are the four fastest-growing cardiac implant segments.